Experimental cell therapy aims to boost immune attack on breast cancer
NCT ID NCT05378464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests the safety of giving specially grown immune cells (T cells) to people with metastatic HER2-positive breast cancer. Participants first receive a vaccine made from their own immune cells plus two drugs (pepinemab and trastuzumab) to help the body fight the cancer. The goal is to find the safest dose of the T cells and see if the combination shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?